发明名称 Corticosteroid compositions
摘要 Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
申请公布号 US9050368(B2) 申请公布日期 2015.06.09
申请号 US200812269816 申请日期 2008.11.12
申请人 Meritage Pharma, Inc. 发明人 Phillips Elaine;Hill Malcolm;Deshmukh Hemant;Johnson Keith;Licalsi Cynthia
分类号 A61K9/14;A01N45/00;A61K31/56;A61K47/38;A61K9/00;A61K31/58;A61K31/575;A61K45/06;A61K47/32;A61K47/36 主分类号 A61K9/14
代理机构 Wilson Sonsini Goodrich & Rosati 代理人 Wilson Sonsini Goodrich & Rosati
主权项 1. An oral liquid pharmaceutical composition comprising a stable dispersion or suspension comprising: a. budesonide in an amount of about 0.02 mg/mL to about 0.75 mg/mL of the composition, b. disodium edetate in an amount of about 0.05 mg/mL to about 25 mg/mL of the composition, c. a buffer, wherein the buffer is chosen from the group consisting of sodium citrate, citric acid, a carbonate buffer, a hydroxide buffer, a phosphate buffer, an acetate buffer, or combinations thereof, d. polysorbate 80 in an amount of about 0.01 mg/mL to about 1 mg/mL of the composition, e. a preservative, wherein the preservative is potassium sorbate present in an amount of about 0.2 mg/mL to about 10 mg/mL of the composition, sodium benzoate present in an amount of about 0.2 mg/mL to about 10 mg/mL of the composition, or a combination thereof, f. a flavoring agent, a sweetener, or a combination thereof, g. dextrose in an amount of 0-250 mg/mL of the composition, h. at least one additional excipient comprising maltodextrin present in an amount of about 10 mg/mL to about 1 g/mL of the composition, and one or more of hydroxyethylcellulose (HEC), hydroxypropylmethyl-cellulose (HPMC), carboxymethyl-cellulose (CMC), microcrystalline cellulose (MCC), carbomer, and combinations thereof, present in an amount of about 5 mg/mL to about 100 mg/mL of the composition; and i. water, wherein the composition is physically and chemically stable, wherein during and after storage the particles of the dispersion or suspension do not cake or aggregate, wherein the composition remains substantially uniform for at least 1 day, and wherein the composition is suitable for single or multiple dose administration, the composition having a viscosity of at least 50 cP.
地址 San Diego CA US